PHOENIX -- A novel transcatheter device that twists the left atrial appendage (LAA) closed from the inside appeared safe in first-in-human results. Among 15 atrial fibrillation patients who received ...

Chicago, Jan. 15, 2026 (GLOBE NEWSWIRE) -- The global left atrial appendage closure devices market was valued at 1.98 billion in 2024 and is expected to reach US$ 9.40 billion by 2033, growing at a ...

Within the last 24 months, I have had financial relationship(s) with the ineligible company or companies listed below: Receive the the latest news, research, and presentations from major meetings ...

Johnson & Johnson MedTech has strengthened its cardiac treatment offerings with the $400 million acquisition of Laminar Inc., a private medical device company headquartered in Santa Rosa, Calif. The ...

Johnson & Johnson MedTech has become the newest competitor in the left atrial appendage (LAA) market after acquiring Laminar. The deal has the New Brunswick, NJ-based company doling out about $400 ...

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson MedTech 1 today announced the completion of the acquisition 2 of Laminar, Inc., a privately-held medical device company focused on eliminating ...

Santé Ventures was the sole venture capital investor in Laminar, which aims to treat persistent atrial fibrillation (AFib) with an innovative solution for the left atrial appendage (LAA) More than 38 ...

WICHITA, Kan. (KSNW) — Via Christi says it is the first hospital in the region to perform a new procedure for atrial fibrillation for patients who can’t tolerate blood thinners. A-Fib, as it is often ...